NeOnc Technologies stock surges on $50 million strategic partnership

Published 29/07/2025, 20:22
© Reuters.

Investing.com -- NeOnc Technologies Holdings Inc (NASDAQ:NTHI) stock jumped 5.3% after the clinical-stage biotechnology company announced signing a definitive agreement for a $50 million strategic partnership with Quazar Investment.

The agreement follows unanimous approval from NeOnc’s Board and involves Quazar acquiring 1.4 million shares at $25 per share, representing a $35 million investment to be held in custody at Morgan Stanley (NYSE:MS). The remaining $15 million will fund Phase 2B clinical trials and infrastructure development across the UAE and MENA region.

Under the partnership structure, 70% of the proceeds will go toward acquiring NeOnc common stock, while 30% is allocated for launching clinical trials and building infrastructure in the Middle East. The transaction must satisfy remaining conditions within 120 days, including legal formation of NuroMENA and NuroCure in Abu Dhabi.

"This definitive agreement sets the stage for accelerated global expansion and scientific innovation," said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc.

NeOnc Technologies, a multi-phase 2 clinical-stage biotechnology company, focuses on developing treatments for brain and central nervous system cancers. The partnership is expected to expand the company’s therapeutic footprint globally while establishing operational presence in the UAE.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.